FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:754-755 March 16, 1995 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Burroughs Wellcome shares the concern expressed by Pourmotabbed (Oct. 27 issue)¹ about confusion between our Lanoxin brand of digoxin and another manufacturer's Levoxine brand of levothyroxine sodium. The medication error described underscores an important patient-safety issue.

Last July, our company mailed all pharmacists a notice informing them of reports of confusion between the Lanoxin and Levoxine brand names. We also asked the company that manufactures Levoxine to change its brand name to avoid situations such as the one Pourmotabbed describes. Lanoxin is a long-established brand name that pharmacists and physicians know. It is also the senior brand . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Carriere, B., Bailey, B., Chabot, G., Lebel, D. (2003). Dispensing Error Leading to Alendronate Ingestion. The Annals of Pharmacotherapy 37: 87-89 [Abstract] [Full Text]  
• Silverman, H.I., Lauvin, R. (1995). More on Skin Cancer after the Extravasation of Doxorubicin. NEJM 333: 257-257 [Full Text]